Tirzepatide
Product Description
OMGENE LIFE SCIENCES PRIVATE LIMITED
-
IN
-
2020On CPHI since
-
50 - 99Employees
Company types
Categories
Specifications
OMGENE LIFE SCIENCES PRIVATE LIMITED
-
IN
-
2020On CPHI since
-
50 - 99Employees
Company types
More Products from OMGENE LIFE SCIENCES PRIVATE LIMITED (44)
-
Product Vasopressin
Indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. -
Product Vismodegib
Indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation. -
Product Complex Semi-synthetic APIs
Micafungin Sodium, Anidulafungin-Fructose, Dalbavancin, Everolimus, Sarecycline, Midostaurin etc. -
Product Omadacycline
A tetracycline class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms (1): Community-acquired bacterial pneumonia (CABP) (1.1); Acute bacterial skin and skin structure infections (ABSSSI) -
Product Semaglutide
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus , to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and est... -
Product Rezafungin
Rezafungin is a next-generation, semi-synthetic, cyclic lipopeptide and echinocandin derivative, with potential antifungal activity. -
Product Cetrorelix Acetate
Indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation. -
Product Degarelix Acetate
Indicated for treatment of patients with advanced prostate cancer. -
Product Apremilast
Indicated in Psoriatic Arthritis, Psoriasis and Oral Ulcers Associated with Behçet’s Disease -
Product Bedaquiline Fumarate
Diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). -
Product Binimetinib
Indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation -
Product Brivaracetam
Indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
OMGENE LIFE SCIENCES PRIVATE LIMITED resources (1)
-
Brochure Brochure of Company
Brochure of the company for referring to Company's work profile, strengths, capabilities and facility information.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance